Premium
Tandem Mass Spectrometry Analysis of Amadori‐Glycated Phosphatidylethanolamine in Human Plasma
Author(s) -
MIYAZAWA TERUO,
OAK JEONGHO,
NAKAGAWA KIYOTAKA
Publication year - 2005
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1333.034
Subject(s) - amadori rearrangement , chemistry , tandem mass spectrometry , mass spectrometry , phosphatidylethanolamine , chromatography , biochemistry , glycation , phospholipid , receptor , phosphatidylcholine , membrane
A bstract : Amadori‐glycated phosphatidylethanolamine (Amadori‐PE), a nonenzymatically glycated lipid formed under hyperglycemic conditions, is known as a reliable indicator of lipid glycation in vivo . We have quantified the Amadori‐PE concentration in human plasma samples using a reverse‐phase liquid chromatography‐tandem mass spectrometry with neutral loss scan or multiple reaction monitoring. Amounts of Amadori‐PE in plasma of diabetic patients (0.15 mol% of PE), diabetic patients with chronic hemodialysis (0.29 mol% of PE), and nondiabetic patients with chronic hemodialysis (0.13 mol% of PE) are higher than that of the control group (0.08 mol% of PE). In addition, the concentration of Amadori‐PE was proportional to that of phosphatidylcholine hydroperoxide, a reliable indicator of membrane lipid peroxidation, in human plasma ( P < 0.05 ). These results indicate that plasma Amadori‐PE‐glycated lipid product formed under hyperglycemic conditions is an inducer of membrane lipid peroxidation, and therefore lipid glycation plays an active part in the development of human disease.